Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.
about
Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremityPrimary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremityGas6 regulates mesangial cell proliferation through Axl in experimental glomerulonephritisManagement of antithrombotic therapy during cardiac implantable device surgeryHow to manage warfarin therapyPharmacogenetics-based warfarin dosing in childrenOral anticoagulants: pharmacodynamics, clinical indications and adverse effectsTraceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivoLong-term anticoagulation. Indications and management.Determination of free and total warfarin concentrations in plasma using UPLC MS/MS and its application to a patient samples.Adverse Interaction between Capecitabine and Warfarin Resulting in Altered Coagulation Parameters: A Review of the Literature Starting from a Case Report.Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin.Inter-relationship among individual vitamin K-dependent clotting factors at different levels of anticoagulationWarfarin dosage requirements: prospective clinical trial of a method for prediction from the response to a single dose.The Smith Kline & French lecture 1987. Clinical pharmacology and the art of bespoke prescribing.Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance.A comprehensive model for the humoral coagulation network in humans.Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases.Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians.The pharmacology and therapeutic use of dabigatran etexilate.Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients.Novel anticoagulants for stroke prevention in patients with atrial fibrillation.Recent advances in anticoagulant drug delivery.Beyond warfarin: The advent of new oral anticoagulants.A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation Proteins.Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes.The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats.Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients.Enhanced Method for Diagnosing Pharmacometric Models: Random Sampling from Conditional Distributions.A Bayesian dose-individualization method for warfarin.Optimal individualized dosing strategies: A pharmacologic approach to developing dynamic treatment regimens for continuous-valued treatments.Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance.The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjects.Interaction between Gemcitabine and Warfarin Causing Gastrointestinal Bleeding in a Patient with Pancreatic Cancer.PharmML in Action: an Interoperable Language for Modeling and Simulation.Monitoring may need to be prolonged in patients given warfarin and amiodarone.
P2860
Q24197472-4D490ABE-C5FA-436B-89FB-DBF541018A62Q24201769-33CEB355-6FBC-4DDC-96E0-F55CEA6CA48AQ24672961-8EC1F158-DF59-415C-AFE6-6E39AE553A8DQ26746160-528E95A8-93EB-456B-9E4E-85B3B8088E0CQ26773328-977A494B-63B0-4DDD-8508-12F3F2520AF4Q27008320-AAA66B58-26CA-4DB0-93A1-C6876B4EF598Q28319507-E0652FA0-EFF0-44B7-A583-1C933F6FCEFBQ28539158-9281ECEA-F481-4891-9917-CD830A161BF1Q33617257-EF596D86-D21C-46F1-8896-0B93BE7E7ABBQ33837117-FEE00C55-C648-4411-B5D9-4C9344E7D968Q34019240-03928948-73E8-4E67-ABD6-21CEBEDF0BF8Q34346399-F09FC628-F40B-411B-B27C-99B134608F7CQ34417128-7C2E751A-2ED0-438B-8A38-6538CCDEE17EQ34417505-6025C5C4-95D5-4B66-AA60-ADA45A660435Q34418034-FDF78F5D-D347-4958-BDB5-E5E12F1D10B9Q34644792-BA123CEA-1E16-4A44-8CC1-AB27DF0FBFD8Q34986144-D0CE8F9A-15DF-4F1B-B251-B7C42E659009Q36054968-3E0A7A5B-00D7-4761-80E3-6AC9B0A4B218Q36330247-D9626B8F-E8D5-4EC6-950B-99110D6A7CDEQ36509202-FF4480F9-569C-4A8A-808D-2E1BD7F89072Q37212206-E4B63C89-95F4-40E0-B1B8-780DA7E240AAQ38080765-3DB06189-5E41-4747-82D5-BDDB26138EE7Q38116770-FFB62590-AFC9-4853-8C5E-F511B4DBC0BBQ38212962-01D4901E-B6EF-4A13-8CB0-185CE6DA6FC0Q38649939-3AE347E4-925F-4F1D-9A70-40D6B08FE523Q38692411-E7A4F84B-BAFE-4992-AC4F-1EACF479DF63Q38730441-3322B30A-8458-480F-8298-7D5DBF7858A3Q38734321-A000BC4D-476E-4541-8124-508FB5532F5AQ38911782-6350D837-E0F8-4310-84BA-3C6D3D3AF3EAQ39023182-89DD887F-7E2B-429B-AA01-A48003BE3A74Q39267258-784271DF-54CF-469F-A343-BAB0B7AAA9ABQ39412843-BAB0FF32-31A6-437D-8171-522F966E8F27Q39483373-FA7AC0FE-6015-4596-920A-513B076E0C12Q40355800-709DAA8B-358F-4CFA-9C0D-EC86AB4955E4Q41009890-5A5FF253-CF6E-48A1-A65A-3BECD675B280Q41118521-103E4947-6F58-4EC1-9706-351D13347FA0Q41762441-92DE5729-A1AC-4D55-B0A7-F7EF478A09DBQ42582492-408E010A-F5FD-4DA4-BBAB-6FF5D8ACF48EQ42621630-A6C32CE8-B01A-45D8-A69B-5F73F1684617Q42682245-FFFB022A-2060-48A8-A655-A7390F5A48C9
P2860
Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.
description
1986 nî lūn-bûn
@nan
1986 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Clinical pharmacokinetics and ...... the dose-effect relationship.
@ast
Clinical pharmacokinetics and ...... the dose-effect relationship.
@en
Clinical pharmacokinetics and ...... the dose-effect relationship.
@nl
type
label
Clinical pharmacokinetics and ...... the dose-effect relationship.
@ast
Clinical pharmacokinetics and ...... the dose-effect relationship.
@en
Clinical pharmacokinetics and ...... the dose-effect relationship.
@nl
prefLabel
Clinical pharmacokinetics and ...... the dose-effect relationship.
@ast
Clinical pharmacokinetics and ...... the dose-effect relationship.
@en
Clinical pharmacokinetics and ...... the dose-effect relationship.
@nl
P1476
Clinical pharmacokinetics and ...... g the dose-effect relationship
@en
P2093
Holford NH
P304
P356
10.2165/00003088-198611060-00005
P50
P577
1986-11-01T00:00:00Z
P6179
1000000977